Optimeos Life Sciences is a Princeton University spinout developing non-viral nanoparticle drug delivery systems for biologics, peptides, RNA and DNA therapeutics. Its patented Coated Inverse NanoCarrier (CINC) process encapsulates multiple payload types into customizable nanocarriers with encapsulation efficiencies reported above 90 percent, and a companion LINC format makes long-acting microparticle depots. The company runs preclinical programs in hepatic gene replacement for Citrullinemia Type 1, in vivo T cell engineering, and a long-acting GLP-1 depot, and partners with pharmaceutical companies on formulation. It operates out of Princeton Innovation Center BioLabs and is backed by SBIR awards and venture investors including Hatch BioFund.